Pharmaceutical Ethics serves as the guiding moral foundation that shapes the conduct and decision-making within the pharmaceutical industry. It is a crucial framework designed to ensure that drug development, production, and distribution align with the principles of patient welfare and societal well-being.
At its core, pharmaceutical ethics underscores the significance of placing patient interests above commercial considerations. This involves promoting fair pricing, ensuring accessibility, and facilitating the equitable distribution of pharmaceutical products to enhance global health outcomes.
The ethical dimensions of pharmaceutical practices extend to the responsible marketing and promotion of drugs. This includes a commitment to accurate and unbiased promotional materials, coupled with ethical engagements with healthcare professionals to prevent undue influence. Upholding the highest standards of integrity is paramount for maintaining public trust and confidence in the industry.
Furthermore, pharmaceutical ethics delicately navigates the intersection of advancing scientific knowledge and safeguarding human rights. It acts as a moral compass, directing the industry toward practices that prioritize patient well-being, uphold integrity, and contribute positively to global health.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia